Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives $43.71 Consensus Price Target from Brokerages

Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the eight brokerages that are currently covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $43.71.

A number of brokerages have recently commented on ARWR. Wall Street Zen raised Arrowhead Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Saturday, June 14th. Citigroup lowered their price target on Arrowhead Pharmaceuticals from $21.00 to $17.00 and set a "neutral" rating on the stock in a report on Tuesday, May 13th. HC Wainwright reaffirmed a "buy" rating and set a $80.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, May 20th. Finally, Chardan Capital reaffirmed a "buy" rating and set a $60.00 target price on shares of Arrowhead Pharmaceuticals in a report on Tuesday, May 13th.

Arrowhead Pharmaceuticals Stock Performance

Shares of ARWR traded down $0.12 during trading hours on Friday, reaching $16.78. 800,545 shares of the company's stock traded hands, compared to its average volume of 1,550,819. The firm has a market capitalization of $2.32 billion, a price-to-earnings ratio of -11.99, a P/E/G ratio of 19.75 and a beta of 0.93. The company has a debt-to-equity ratio of 0.31, a current ratio of 5.15 and a quick ratio of 5.15. Arrowhead Pharmaceuticals has a twelve month low of $9.57 and a twelve month high of $30.41. The business's fifty day simple moving average is $15.45 and its two-hundred day simple moving average is $16.39.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The biotechnology company reported $2.75 EPS for the quarter, beating analysts' consensus estimates of ($0.06) by $2.81. The business had revenue of $542.71 million for the quarter, compared to analyst estimates of $116.27 million. During the same period last year, the business posted ($1.02) earnings per share. Analysts predict that Arrowhead Pharmaceuticals will post -2.42 earnings per share for the current year.

Insider Transactions at Arrowhead Pharmaceuticals

In related news, CEO Christopher Richard Anzalone sold 50,800 shares of Arrowhead Pharmaceuticals stock in a transaction dated Friday, April 11th. The stock was sold at an average price of $11.49, for a total transaction of $583,692.00. Following the transaction, the chief executive officer directly owned 3,921,255 shares of the company's stock, valued at $45,055,219.95. The trade was a 1.28% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 4.30% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Arrowhead Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the stock. Focus Partners Wealth increased its stake in Arrowhead Pharmaceuticals by 1,339.5% in the 1st quarter. Focus Partners Wealth now owns 16,252 shares of the biotechnology company's stock worth $207,000 after purchasing an additional 15,123 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Arrowhead Pharmaceuticals by 138.0% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,785,062 shares of the biotechnology company's stock worth $60,962,000 after purchasing an additional 2,774,933 shares in the last quarter. Empowered Funds LLC increased its stake in Arrowhead Pharmaceuticals by 6.9% in the 1st quarter. Empowered Funds LLC now owns 15,252 shares of the biotechnology company's stock worth $194,000 after purchasing an additional 979 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in Arrowhead Pharmaceuticals by 34.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,741,666 shares of the biotechnology company's stock worth $22,189,000 after purchasing an additional 447,456 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd increased its stake in Arrowhead Pharmaceuticals by 40.9% in the 1st quarter. Dynamic Technology Lab Private Ltd now owns 26,969 shares of the biotechnology company's stock worth $343,000 after purchasing an additional 7,827 shares in the last quarter. Hedge funds and other institutional investors own 62.61% of the company's stock.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.